Changes in Cardiac Function and Exercise Capacity Following Ferric Carboxymaltose Administration in HFrEF Patients with Iron Deficiency

Changes in Cardiac Function and Exercise Capacity Following Ferric Carboxymaltose Administration in HFrEF Patients with Iron Deficiency

<b>Background/Objectives:</b> Iron deficiency (ID) is a common and prognostically relevant comorbidity in heart failure with reduced ejection fraction (HFrEF). It contributes to reduced functional status, exercise capacity, and survival. Intravenous ferric carboxymaltose (FCM) improves s...

Full description

Saved in:
Bibliographic Details
Main Authors: Anastasios Tsarouchas, Constantinos Bakogiannis, Dimitrios Mouselimis, Christodoulos E. Papadopoulos, Efstratios K. Theofillogiannakos, Efstathios D. Pagourelias, Ioannis Kelemanis, Aristi. Boulmpou, Antonios P. Antoniadis, Nikolaos Fragakis, Georgios Efthimiadis, Theodoros D. Karamitsos, Vassilios P. Vassilikos
Format: Article
Language:English
Published: MDPI AG 2025-08-01
Series:Diagnostics
Subjects:
HFrEF
ferric carboxymaltose
strain imaging
iron deficiency
exercise capacity
diastolic dysfunction
Online Access:https://www.mdpi.com/2075-4418/15/15/1941
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:<b>Background/Objectives:</b> Iron deficiency (ID) is a common and prognostically relevant comorbidity in heart failure with reduced ejection fraction (HFrEF). It contributes to reduced functional status, exercise capacity, and survival. Intravenous ferric carboxymaltose (FCM) improves symptoms, but its effect on cardiac structure and function remains incompletely understood. The aim of this study was to assess the impact of intravenous FCM on echocardiographic indices of left ventricular (LV), left atrial (LA), and right ventricular (RV) morphology and function in HFrEF patients with ID and determine whether these changes correlate with improvements in exercise capacity. <b>Methods:</b> This sub-analysis of the RESAFE-HF registry (NCT04974021) included 86 HFrEF patients with ID (median age 71.8 years, 83% male). Transthoracic echocardiography was performed at baseline and 12 months post-FCM. Parameters assessed included LV ejection fraction (LVEF), LV global longitudinal strain (GLS), LV diastolic function grade, LAVi, LA strain, TAPSE, and RV free wall strain (FWS). Peak VO<sub>2</sub> was measured to assess exercise capacity. <b>Results:</b> LVEF improved from 29.3 ± 7.8% to 32.5 ± 10.6% (<i>p</i> < 0.001), LV GLS from −7.89% to −8.62%, and the LV diastolic dysfunction grade improved (<i>p</i> < 0.001). LAVi, peak LA strain, TAPSE, and RV FWS also showed significant improvement. Peak VO<sub>2</sub> increased from 11.3 ± 3.2 to 12.1 ± 4.1 mL/min/kg (<i>p</i> < 0.001). Improvements in LVEF, RV FWS, and LV GLS were independent predictors of VO<sub>2</sub> increase (<i>p</i> < 0.001, <i>p</i> < 0.001, and <i>p</i> = 0.01, respectively), explaining 42% of the variance. <b>Conclusions:</b> FCM therapy improves biventricular and atrial function, with echocardiographic gains correlating with an enhanced exercise capacity in HFrEF patients with ID.
ISSN:2075-4418

Similar Items